Cytomegalovirus pneumonia after anti-CC-chemokine receptor 4 monoclonal antibody (Mogamulizumab) therapy in an angioimmunoblastic T-cell lymphoma patient

Internal Medicine

Volumn 55, Issue 6, 2016, Pages 673-675

  Ishii, Yoshimi ^a   Itabashi, Megumi ^a   Numata, Ayumi ^a   Yamamoto, Wataru ^a   Motohashi, Kenji ^a   Hagihara, Maki ^a   Matsumoto, Kenji ^a   Fujisawa, Shin ^a  

^a YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

Author keywords

Cytomegalovirus pneumonia; Lymphoma; Mogamulizumab

Indexed keywords

CARBOPLATIN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; GANCICLOVIR; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; MOGAMULIZUMAB; PIPERACILLIN PLUS TAZOBACTAM; PREDNISOLONE; VINCRISTINE; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CCR4 PROTEIN, HUMAN; CHEMOKINE RECEPTOR CCR4; CISPLATIN; MONOCLONAL ANTIBODY; PREDNISONE;

ADULT; ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; ARTICLE; BONE MARROW BIOPSY; BONE PAIN; CANCER CHEMOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS PNEUMONIA; DEATH; FEVER; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; LYMPH NODE; LYMPHOMA CELL; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; PANCYTOPENIA; PERICARDIAL EFFUSION; PLEURA EFFUSION; POSITRON EMISSION TOMOGRAPHY; RASH; VIRUS PNEUMONIA; ANTAGONISTS AND INHIBITORS; CYTOMEGALOVIRUS INFECTIONS; DISEASE COURSE; DRUG RESISTANCE; FATALITY; IMMUNOBLASTIC LYMPHADENOPATHY; IMMUNOLOGY; LYMPHOMA, T-CELL; PATHOPHYSIOLOGY; PNEUMONIA, VIRAL; VIROLOGY;

ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIVIRAL AGENTS; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOMEGALOVIRUS INFECTIONS; DISEASE PROGRESSION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FATAL OUTCOME; HUMANS; IMMUNOBLASTIC LYMPHADENOPATHY; LYMPHOMA, T-CELL; MALE; METHYLPREDNISOLONE; MIDDLE AGED; PNEUMONIA, VIRAL; PREDNISONE; RECEPTORS, CCR4; VINCRISTINE;

EID: 84960970478     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.55.5644     Document Type: Article

References (15)

1. Swerdlow SH, Campo E, Harris NL. World Health Organization Classification of Tumors of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon, France, 2008.
2. Mourad N, Mounier N, Brière J, et al; Groupe d'Etude des Lymphomes de l'Adulte. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood 111: 4463-4470, 2008.
3. Zhao S, Zhang L, Zhang M, et al. Angioimmunoblastic T-cell lymphoma: the effect of initial treatment and microvascular density in 31 patients. Med Oncol 29: 2311-2316, 2012.
4. Ishida T, Joh T, Uike N, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemialymphoma: a multicenter phase II study. J Clin Oncol 30: 837- 842, 2012.
5. Ishida T, Inagaki H, Utsunomiya A, et al. CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NKcell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. Clin Cancer Res 10: 5494-5500, 2004.
6. Ohshima K, Karube K, Kawano R, et al. Classification of distinct subtypes of peripheral T-cell lymphoma unspecified, identified by chemokine and chemokine receptor expression: analysis of prognosis. Int J Oncol 25: 605-613, 2004.
7. Ogura M, Ishida T, Hatake K, et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol 32: 1157-1163, 2014.
8. Lundin J, Hagberg H, Repp R, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 101: 4267-4272, 2003.
9. Aksoy S, Harputluoglu H, Kilickap S, et al. Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma 48: 1307- 1312, 2007.
10. Gallamini A, Zaja F, Patti C, et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral Tcell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 110: 2316- 2323, 2007.
11. Ohyama Y, Kumode T, Eguchi G, Yamaguchi T, Maeda Y. Induction of molecular remission by using anti-CC-chemokine receptor 4 (anti-CCR4) antibodies for adult T cell leukemia: a risk of opportunistic infection after treatment with anti-CCR4 antibodies. Ann Hematol 93: 169-171, 2014.
12. Ishida T, Jo T, Takemoto S, et al. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study. Br J Haematol 169: 672-682, 2015.
13. Chemaly RF, Torres HA, Hachem RY, et al. Cytomegalovirus pneumonia in patients with lymphoma. Cancer 104: 1213-1220, 2005.
14. Tay MR, Lim ST, Tao M, Quek RH, Tay K, Tan TT. Cytomegalovirus infection and end-organ disease in Asian patients with lymphoma receiving chemotherapy. Leuk Lymphoma 55: 182-187, 2014.
15. Chang H, Tang TC, Hung YS, Lin TL, Kuo MC, Wang PN. Cytomegalovirus infection in non-transplant patients with hematologic neoplasms: a case series. Chang Gung Med J 34: 65-74, 2011.